Published in Biotech Business Week, October 6th, 2003
Psychiatric Genomics will use the funds to identify gene expression patterns of diseases (disease signatures) and drugs (drug signatures) to find next-generation compounds to treat psychiatric diseases, and will seek established partners for their development/commercialization.
In November 2002, SMRI invested US$1 million dollars in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.